Drug Profile
CS 1036
Alternative Names: CS-1036Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 26 May 2011 Discontinued - Phase-II for Diabetes mellitus in Asia (PO)
- 26 May 2011 Discontinued - Phase-II for Diabetes mellitus in Japan (PO)
- 21 May 2010 Phase-II clinical trials in Diabetes mellitus in Asia (PO)